Adams Paul C
University Hospital, London, Ont., Canada.
Acta Haematol. 2009;122(2-3):134-9. doi: 10.1159/000243797. Epub 2009 Nov 10.
Hemochromatosis has generally been considered to be a genetic disease in which progressive iron accumulation over many years can lead to cirrhosis of the liver, hepatocellular carcinoma, diabetes, cardiomyopathy, and arthropathy. Iron depletion by phlebotomy has been the recommended therapy although a randomized trial of phlebotomy versus no treatment has never been reported. Since the discovery of the HFE gene in 1996, it has been possible to predict the risk of developing iron overload by a simple blood test to detect C282Y homozygotes of the HFE gene. The application of the hemochromatosis genetic test in large population studies often initiated to investigate other diseases has provided a fascinating glimpse into the natural history of untreated C282Y homozygotes followed for over 20 years without phlebotomy treatment. These observations are summarized in this review article which raises questions about the need for phlebotomy in all C282Y homozygous patients.
血色素沉着症通常被认为是一种遗传性疾病,多年来铁的逐渐积累可导致肝硬化、肝细胞癌、糖尿病、心肌病和关节病。放血排铁一直是推荐的治疗方法,尽管从未有过放血与不治疗对比的随机试验报告。自1996年发现HFE基因以来,通过简单的血液检测来检测HFE基因的C282Y纯合子,就能够预测发生铁过载的风险。在通常为研究其他疾病而开展的大规模人群研究中应用血色素沉着症基因检测,让我们得以一窥未接受放血治疗、随访超过20年的C282Y纯合子的自然病史。这篇综述文章总结了这些观察结果,同时也引发了关于是否有必要对所有C282Y纯合患者进行放血治疗的疑问。